Our Vision
Enabling personalized
medicine for you
Our DNA is unique and it is the most precious thing we have. GenomSys wants everyone to protect it and leverage it to truly enjoy personalized medicine to his/her own uniqueness.
Thanks to the innovative technologies developed by our engineers and bio-informaticians, today everybody can access their own genomic data, store it safely in their smartphone, order analyses, read the results and share them with their doctor.
A true digital revolution which makes personalized medicine accessible to everyone.
Personalized Medicine
One-size-fits-all has been the basis of medicine – thanks to advancements in medicine and genomics, that’s no more the case, as nobody is equal to anyone else, and drugs act differently based on DNA. GenomSys enables everyone to access and check its DNA whenever and wherever they need it.
Bring Genomics into the Digital Age
Thanks to the development of the fully digital MPEG-G standard and its compliant analytical tools, GenomSys takes genomics truly into the digital age. From the dungeons of labs and remote servers, DNA analysis is brought to everyone’s smartphone, with a user-friendly interface, simple and easy as watching a movie.
Security and Interoperability
GenomSys leverages MPEG-G built-in encryption to ensure that everyone’s most sensitive information is carefully protected – and in their own hands!, while adopting an international standard to guarantee full interoperability and hence to future-proof both customers’ data and its own solutions.
Our Expertise
GenomSys is a Swiss company with a multicultural team of experienced and talented geneticists, bio-informaticians, mobile developers and software engineers led by senior management with long-standing activity in digital health, software development and genomics.
Our history
Founded in 2016 by a group of experienced engineers and bio-informaticians under the leadership of Claudio Alberti, our CTO, GenomSys is a Swiss company developing state-of-the-art technology and services for the efficient analysis and secure management of genomic information.
The company is a pioneer in the development of open standards for genomic data storage and processing – it led the process of standardization of ISO/IEC 23092 (MPEG-G) – and in the implementation of compliant software and tools for its effective application.
In October 2019, GenomSys secured a CHF9.3 million Series A funding to take the development of the company to the next stage.
Now GenomSys is taking the next step, enabling laboratories and end-users to take advantage of the new standard: MPEG-G native analytical pipelines for more efficient storage and focused analyses via selective access, and the ability for people to store and analyze their own genomic data in their smartphones, bringing genomics into the mobile world.
In doing so, GenomSys defines a new paradigm with a highly differentiated solution: a consistent value proposition emphasizing privacy and convenience to truly deliver personalized medicine to individuals by leveraging the uniqueness of the new digital genomic standard and the pervasiveness of mobile, directly or through business partners.
GenomSys headquarters are in the Swiss Health Valley, at the center of a hub of technology and genomic innovation around the research centers of the Ecole Polytechnique Fédérale de Lausanne and the Swiss Genome Center. The company recently opened an additional scientific center in Ticino, an emerging hub for innovation in biotechnology and digital developments in the south of Switzerland.
Investors
Preon Capital Partners
Based in Geneva since 2014, Preon Capital Partners is the family office of one of the most successful business angels in Europe and operates as an independent asset manager and financial advisory company. Our family office is a well known provider of seed and early-stage venture capital. The company invests mainly in equity with a particular focus in technology startups that try to anticipate future global trends.
Dolby Family Ventures
Based in San Francisco, Dolby Family Ventures is an early stage venture capital firm that invests globally in three broad sectors: information technology, biotechnology, and breakthrough innovation companies driving the convergence between digital technologies and healthcare. Our Life Sciences investing practice is exclusively focused on Neurodegeneration, targeting disease modifying therapeutics to cure Alzheimer’s Disease and novel approaches to treat Clinical Depression. Our current active portfolio exceeds 50 companies, with focused themes outside of biotech including Aerospace, Augmented Reality, Advanced Digital Signal Processing, Artificial Intelligence, Robotics, Bio Informatics, and Quantum Computing.
Elysia Capital
Elysia Capital is the single Family Office of the Buono-Lopera family based in London and Turin. Sustainable innovation, uniqueness, social well-being, know-how: these are the keywords we seek in the projects we support, as we think that good ideas can really change the world. We believe in the value of know-how, in expertise and in teamwork. Our mission is to turn sustainable projects into great enterprises by investing in their evolution as a means to improve social well-being. Our Company invests mainly in the field of sustainable Innovation, Education, Well-being, Arts and Culture.
Club degli investitori
Club degli Investitori is the most active business angel network in Italy. Started in Turin in 2008 by four entrepreneurs, Club degli Investitori represents today a novel model of investing in Italy. More than 170 member investors invested with 16 million Euro on a portfolio of 25 companies and completed 3 exits. In 2018, Club degli Investitori invested more than 3 million Euros, with a goal of 5 million euros in 2019.
Pygar
Based in Turin and founded in 2018, Pygar is Michele Denegri’s investment company.
Pygar has been set up in order to carry on Finde’s last 20 years of investment experience and philosophy, truly representing its operational evolution.
Pygar exclusively invests its own capitals, guaranteeing outstanding flexibility in the choice of investment opportunities and long term support.
